二甲双胍、阿卡波糖及其联合应用对烟酰胺/链脲佐菌素诱导的2型糖尿病大鼠血清内脂素水平的影响
Effect of Metformin, Acarbose and Their Combination on the Serum Visfatin Level in Nicotinamide/Streptozocin-Induced Type 2 Diabetic Rats.
作者信息
Salemi Zahra, Rafie Elham, Goodarzi Mohamad Taghi, Ghaffari Mohamad Ali
机构信息
Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, IR Iran; Department of Biochemistry, Arak University of Medical Sciences, Arak, IR Iran.
Department of Biochemistry, Arak University of Medical Sciences, Arak, IR Iran.
出版信息
Iran Red Crescent Med J. 2016 Mar 2;18(3):e23814. doi: 10.5812/ircmj.23814. eCollection 2016 Mar.
BACKGROUND
Diabetes mellitus is a chronic metabolic disease with life-threatening complications. Metformin and acarbose are two oral antidiabetic drugs.
OBJECTIVES
This experimental study was designed and carried out at the Arak University of Medical Sciences in Arak, Iran, to investigate the effects of these drugs (both alone and in combination) on glycemic control, lipid profile, and serum visfatin levels in nicotinamide/streptozotocin type 2 diabetic rats.
MATERIALS AND METHODS
Type 2 diabetes was induced in 30 male Wistar rats by the administration of streptozotocin (STZ) (60 mg/kg body weight) intraperitoneally (IP) 15 minutes after the IP administration of nicotinamide (110 mg/kg body weight). After one week, the diabetic rats were randomly divided into four groups. Three diabetic groups were treated with 150 mg/kg/day of metformin, acarbose (40 mg/100 g of diet), or a combination of the two for six weeks, respectively. Biochemical parameters, including fasting blood glucose, glycated hemoglobin, lipid profile, insulin, and visfatin were assessed and compared with those of the control diabetic group.
RESULTS
The data showed metformin, acarbose, and acarbose + metformin downregulated visfatin levels in diabetic rats, but only the reduction in metformin-treated rats was significant (162 ± 21.7, 195.66 ± 6.45 (ng/l), P = 0.001). Fasting blood glucose and glycated hemoglobin decreased significantly in all treated rats, specifically in the treated group that received the two drugs in combination. The serum insulin level was also reduced in all treated groups, and it was significant in the acarbose (P < 0.05) and the combination therapy groups (P < 0.05). The lipid profile improved in all treated groups.
CONCLUSIONS
Compared with acarbose or metformin monotherapy, the addition of acarbose to metformin had superior antihyperglycemia efficacy and provided an efficacious and safe alternative for the treatment of type 2 diabetic rats. Acarbose/metformin reduced the fasting blood glucose and glycated hemoglobin without significant changes in serum visfatin levels.
背景
糖尿病是一种伴有危及生命并发症的慢性代谢性疾病。二甲双胍和阿卡波糖是两种口服抗糖尿病药物。
目的
本实验研究在伊朗阿拉克医科大学设计并开展，旨在探究这些药物（单独使用及联合使用）对烟酰胺/链脲佐菌素诱导的2型糖尿病大鼠血糖控制、血脂谱及血清内脂素水平的影响。
材料与方法
30只雄性Wistar大鼠腹腔注射烟酰胺（110mg/kg体重）15分钟后，腹腔注射链脲佐菌素（STZ）（60mg/kg体重）诱导2型糖尿病。一周后，将糖尿病大鼠随机分为四组。三个糖尿病组分别接受150mg/kg/天的二甲双胍、阿卡波糖（4mg/100g饮食）或二者联合治疗六周。评估包括空腹血糖、糖化血红蛋白、血脂谱、胰岛素和内脂素在内的生化参数，并与对照糖尿病组进行比较。
结果
数据显示，二甲双胍、阿卡波糖及阿卡波糖+二甲双胍均可下调糖尿病大鼠内脂素水平，但仅二甲双胍治疗组的降低具有显著性（162±21.7，195.66±6.45（ng/l），P=0.001）。所有治疗组大鼠的空腹血糖和糖化血红蛋白均显著降低，尤其是联合使用两种药物的治疗组。所有治疗组的血清胰岛素水平也降低，阿卡波糖组（P<0.05）和联合治疗组（P<0.05）降低具有显著性。所有治疗组的血脂谱均有所改善。
结论
与阿卡波糖或二甲双胍单药治疗相比，二甲双胍联合阿卡波糖具有更好的抗高血糖疗效，为2型糖尿病大鼠的治疗提供了一种有效且安全的替代方案。阿卡波糖/二甲双胍降低了空腹血糖和糖化血红蛋白，而血清内脂素水平无显著变化。
Zotero 插件